Genmab A/S ADS GMAB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T18:10:49.228Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:10:37.814384776Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T18:05:05.917774+00:00
Genmab A/S ADS options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 54.53 | 49.5% | 7.6% | 47.62 | 47.6% | 7.5% |
| 25Δ | 54.04 | 48.7% | 7.0% | 48.47 | 45.2% | 6.0% |
| 30Δ | 53.54 | 47.9% | 6.3% | 49.31 | 42.8% | 4.6% |
| 35Δ | 53.04 | 47.1% | 5.6% | 50.10 | 41.2% | 3.3% |
| 40Δ | 52.54 | 46.3% | 4.9% | 50.64 | 43.2% | 3.1% |
| 45Δ | 52.05 | 45.4% | 4.2% | 51.18 | 45.3% | 2.8% |
| 50Δ | 51.55 | 44.6% | 3.6% | 51.73 | 47.3% | 2.5% |
| 55Δ | 51.05 | 43.8% | 2.9% | 52.27 | 49.4% | 2.2% |
| 60Δ | 50.55 | 43.0% | 2.2% | 52.81 | 51.4% | 1.9% |
| 65Δ | 50.05 | 42.2% | 1.5% | 53.35 | 53.4% | 1.7% |
| 70Δ | 49.05 | 49.0% | 1.3% | 53.89 | 55.5% | 1.4% |
| 75Δ | 47.98 | 56.8% | 1.1% | 54.43 | 57.5% | 1.1% |
| 80Δ | 46.91 | 64.6% | 1.0% | 54.97 | 59.6% | 0.8% |
20Δ
- Pseudo strike
- 54.53
- IV
- 49.5%
- B/E move
- 7.6%
- Pseudo strike
- 47.62
- IV
- 47.6%
- B/E move
- 7.5%
25Δ
- Pseudo strike
- 54.04
- IV
- 48.7%
- B/E move
- 7.0%
- Pseudo strike
- 48.47
- IV
- 45.2%
- B/E move
- 6.0%
30Δ
- Pseudo strike
- 53.54
- IV
- 47.9%
- B/E move
- 6.3%
- Pseudo strike
- 49.31
- IV
- 42.8%
- B/E move
- 4.6%
35Δ
- Pseudo strike
- 53.04
- IV
- 47.1%
- B/E move
- 5.6%
- Pseudo strike
- 50.10
- IV
- 41.2%
- B/E move
- 3.3%
40Δ
- Pseudo strike
- 52.54
- IV
- 46.3%
- B/E move
- 4.9%
- Pseudo strike
- 50.64
- IV
- 43.2%
- B/E move
- 3.1%
45Δ
- Pseudo strike
- 52.05
- IV
- 45.4%
- B/E move
- 4.2%
- Pseudo strike
- 51.18
- IV
- 45.3%
- B/E move
- 2.8%
50Δ
- Pseudo strike
- 51.55
- IV
- 44.6%
- B/E move
- 3.6%
- Pseudo strike
- 51.73
- IV
- 47.3%
- B/E move
- 2.5%
55Δ
- Pseudo strike
- 51.05
- IV
- 43.8%
- B/E move
- 2.9%
- Pseudo strike
- 52.27
- IV
- 49.4%
- B/E move
- 2.2%
60Δ
- Pseudo strike
- 50.55
- IV
- 43.0%
- B/E move
- 2.2%
- Pseudo strike
- 52.81
- IV
- 51.4%
- B/E move
- 1.9%
65Δ
- Pseudo strike
- 50.05
- IV
- 42.2%
- B/E move
- 1.5%
- Pseudo strike
- 53.35
- IV
- 53.4%
- B/E move
- 1.7%
70Δ
- Pseudo strike
- 49.05
- IV
- 49.0%
- B/E move
- 1.3%
- Pseudo strike
- 53.89
- IV
- 55.5%
- B/E move
- 1.4%
75Δ
- Pseudo strike
- 47.98
- IV
- 56.8%
- B/E move
- 1.1%
- Pseudo strike
- 54.43
- IV
- 57.5%
- B/E move
- 1.1%
80Δ
- Pseudo strike
- 46.91
- IV
- 64.6%
- B/E move
- 1.0%
- Pseudo strike
- 54.97
- IV
- 59.6%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 54.20% | |
| 50.83% | |
| 54.12% | |
| 56.81% | |
| 54.39% | |
| 50.13% | |
| 49.00% | |
| 48.37% | |
| 43.26% | |
| 48.15% |
Biotechnology
GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Description unavailable
More →GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Description unavailable
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →